MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Brigham and Women's Hospital · Howard Hughes Medical Institute · +3 more institutions
Abstract
Recently, a gain-of-function MPL mutation, MPLW515L, was described in patients with JAK2V617F-negative myelofibrosis with myeloid metaplasia (MMM). To gain more information on mutational frequency, disease specificity, and clinical correlates, genomic DNA from 1182 patients with myeloproliferative and other myeloid disorders and 64 healthy controls was screened for MPL515 mutations, regardless of JAK2V617F mutational status: 290 with MMM, 242 with polycythemia vera, 318 with essential thrombocythemia (ET), 88 with myelodysplastic syndrome, 118 with chronic myelomonocytic leukemia, and 126 with acute myeloid leukemia (AML). MPL515 mutations, either MPLW515L (n = 17) or a previously undescribed MPLW515K (n = 5),…
Citation impact
- FWCI
- 36.25
- Percentile
- 100%
- References
- 24
Authors
14- APAnimesh PardananiCorresponding
Brigham and Women's Hospital, Howard Hughes Medical Institute, Harvard University, Dana-Farber Cancer Institute, Mayo Clinic in Arizona
- RLRoss L. Levine
Brigham and Women's Hospital, Howard Hughes Medical Institute, Harvard University, Dana-Farber Cancer Institute, Mayo Clinic in Arizona
- TLTerra L. Lasho
Brigham and Women's Hospital, Howard Hughes Medical Institute, Harvard University, Dana-Farber Cancer Institute, Mayo Clinic in Arizona
- YPYana Pikman
Brigham and Women's Hospital, Howard Hughes Medical Institute, Harvard University, Dana-Farber Cancer Institute, Mayo Clinic in Arizona
- RARuben A. Mesa
Brigham and Women's Hospital, Howard Hughes Medical Institute, Harvard University, Dana-Farber Cancer Institute, Mayo Clinic in Arizona
Topics & keywords
- Polycythemia vera
- Myelofibrosis
- Essential thrombocythemia
- Myeloid leukemia
- Chronic myelomonocytic leukemia
- Myeloid
- Myeloproliferative Disorders
- Medicine
- Good health and well-being